EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 13th, 2024 • Sutro Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License Agreement (this “Agreement”) is dated as of March 29, 2024 (the “Effective Date”) by and between Sutro Biopharma, Inc., a corporation organized under the laws of Delaware having a place of business at 111 Oyster Point Boulevard, South San Francisco, CA 94080, USA (“Sutro”), and Ipsen Pharma SAS, a corporation organized under French law having a place of business at 65 Quai George Gorse, 92100 Boulogne-Billancourt, France (“Ipsen”). Sutro and Ipsen may be referred to herein as a “Party” or, collectively, as “Parties”.
